ABSTRACT
Objective:To investigate the effects of butylphthalide combined with ozagrel sodium on the National Institutes of Health Stroke Scale (NIHSS) score, activities of daily living (ADL) score, and coagulation function in patients with acute cerebral infarction.Methods:Ninety-four patients with acute cerebral infarction who were admitted to Gujiao Medical Group Central Hospital from January 2019 to November 2021 were included in this study. They were randomly assigned to undergo treatment with either ozagrel sodium (control group, n = 47) or butylphthalide combined with ozagrel sodium (observation group, n = 47) for 14 consecutive days. Before and after treatment, NIHSS score, ADL score, coagulation function (thrombin time, prothrombin time, D-dimer, activated partial thrombin time), bilateral middle cerebral artery blood flow status (mean blood flow velocity (Vm), resistance index, pulsatility index), brain tissue damage factor (brain natriuretic peptide, neuron-specific enolase, S100 β protein) and the incidence of adverse drug reactions were compared between the two groups. Results:Before treatment, there were no significant differences in NIHSS and ADL scores between the two groups (both P > 0.05). After treatment, the NIHSS score was significantly lower in the observation group than that in the control group [(8.70 ± 1.62) points vs. (9.45 ± 1.2) points, t = 2.51, P < 0.05]; the ADL score was significantly higher in the observation group than that in the control group [(65.15 ± 7.41) points vs. (61.20 ± 6.32) points, t = 2.78, P < 0.05]. Before treatment, there were no significant differences in thrombin time, prothrombin time, D-dimer, and activated partial thrombin time between the two groups (all P > 0.05). After treatment, thrombin time, prothrombin time, and activated partial thrombin time were significantly higher in the observation group than those in the control group ( t = 4.34, 3.00, 2.63, all P < 0.05). After treatment, D-dimer level in the observation group was significantly lower than that in the control group ( t = 3.39, P < 0.05). Before treatment, mean blood flow velocity, resistance index, and pulsatility index were similar between the two groups (all P > 0.05). After treatment, the mean blood flow velocity in the observation group was significantly higher than that in the control group ( t = 3.23, P < 0.05). The pulsatility index and resistance index were significantly lower in the observation group than those in the control group ( t = 2.14, 3.16, both P < 0.05). Before treatment, there were no significant differences in brain natriuretic peptide, neuron-specific enolase, and S100 β protein levels between the two groups (all P > 0.05). After treatment, brain natriuretic peptide, neuron-specific enolase, and S100 β protein levels in the observation group were significantly lower than those in the control group ( t = 3.09, 2.18, 3.33, all P < 0.05). There was no significant difference in incidence of adverse reactions between the observation and control groups [6.38% (3/47) vs. 2.13% (1/47), P > 0.05]. Conclusion:Butylphthalide combined with ozagrel sodium for the treatment of acute cerebral infarction can reduce neurological dysfunction and brain tissue injury, and improve coagulation function, hemodynamic state of the middle cerebral artery, and activities of daily life, without increasing adverse reactions.
ABSTRACT
OBJECTIVES: To investigate the safety and efficacy of combined tirofiban-ozagrel therapy for treating progressive stroke patients out of thrombolytic therapy time window. METHODS: This prospective, double-blind, randomized controlled study included 337 patients who had experienced an acute ischemic stroke between November 2017 and December 2018. All patients were randomized into three groups: 1) the tirofiban/ozagrel group (n=113), 2) the tirofiban group (n=110), and 3) the ozagrel group (n=114). The platelet aggregation (PAG), thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FIB) levels in the patients from these groups were evaluated before starting treatment and then, at 24h, 7 days, and 14 days after treatment. The National Institutes of Health Stroke Scale (NIHSS) scores were evaluated before treatment and then, 24h, 1 week, 2 weeks, and 4 weeks after treatment. The Barthel Index (BI) score was used to measure safety, and the modified Rankin scale (mRS) was used to evaluate disability following 3 months of treatment. The risk factors affecting clinical outcomes were analyzed using logistic multivariate regression. RESULTS: The mean NIHSS score for all the patients was 13.17±3.13 before treatment, and no significant difference between the basic clinical parameters of the three patient groups was found. Following treatment, both PAG and FIB were significantly reduced compared with the baseline (p<0.05). The levels of PAG and FIB in the tirofiban/ozagrel group were significantly lower than those in the tirofiban and ozagrel groups at 24h and 7 days after treatment (p<0.05). The NIHSS score decreased significantly in all treatment groups (p<0.05). The tirofiban/ozagrel NIHSS scores were significantly lower than that of the tirofiban and ozagrel groups at 24h, 1 week, and 2 weeks post initiation (p<0.05 for all). There were no significant differences in the BI and mRS scores or the intracranial hemorrhage rates; further, age, sex, Trial of ORG 10172 in acute stroke treatment (TOAST) type, baseline NIHSS and 24-h NIHSS scores, baseline thrombus-related factors, and treatment methods were shown to not be independent risk factors for clinical outcomes. CONCLUSION: The combination of tirofiban and ozagrel, as well as monotherapy with either tirofiban or ozagrel, transiently improves the neural function of patients and reduces platelet aggregation and fibrinogen formation in the first 4 weeks following a stroke event; additionally, none of these treatments increased the risk for hemorrhage in these progressive stroke patients over a 3-month period.
Subject(s)
Humans , Brain Ischemia/drug therapy , Stroke/drug therapy , Thrombolytic Therapy , Cerebral Infarction/drug therapy , Double-Blind Method , Prospective Studies , Treatment Outcome , Tirofiban/therapeutic use , MethacrylatesABSTRACT
Objective: To study the activity of ozagrel sodium alone and in combination with the atypical antipsychotic drug on Red blood cell distribution width (RDW-CV) along with different doses and their comparison in rats. Method: This experimental study consisted of 120 albino rats of both gender, they were of 310-350 g, there were 10 groups which consists of each of 12 rats (n=12). Rats were treated with an accurate dose of ozagrel and atypical antipsychotic (Zuclopenthixol cis isomer of clopenthixol) alone and in combination for 3-weeks (21 days). We obtained blood sample at 0, 7th, 14th and last day of the study. Red blood distribution widths were measured from blood tests by utilizing standard medical laboratory technique. Red blood cell distribution width (RDW-CV) was measured by using the coefficient of variation indicator. Results were gathered and summarized by applying statistics. The comparison was formed between all days value to zero-day. Results: Minimum dose treated groups by both medications showed an increase and RDW-CV, but maximum dose showed p<0.001 decreases in RDW-CV in individual groups of drugs treatment and in case of RDW-CV maximum dose showed an increasing trend with p<0.001 in the combination groups. Conclusion: Maximum dose of ozagrel may cause a decrease in RDW-CV alone and it may cause an increase in (RDW-CV) with a combination of atypical antipsychotic drug.
ABSTRACT
Objective To investigate the clinical curative effect of ozagrel and edaravone in the treatment of cerebral ischemic stroke.Methods 100 patients with cerebral ischemic stroke were chosen to research,and they were divided into control group and research group,50 cases in each group.The control group was treated with ozagrel,the research group was treated with edaravone on the basis of control group.The activities of daily living scale(ADL index score) and the Scandinavian Stroke Scale(SSS score) before treatment,7 d and 14 d after treatment were observered,and the clinical curative effect between the two group was compared.Results The total effective rate of the research group was higher than that of the control group (92.00％ vs,72.00％),the difference was statistically significant (x2 =6.775,P ＜0.05).There was no statistically significant difference in SSS score between the two groups before treatment (t =0.159,P ＞ 0.05).After treatment,the SSS score were significantly reduced compared with before treatment,the differences were statistically significant (t =4.552,10.023,0.616,4.854,all P ＜ 0.05).At 7d and 14d after treatment,the SSS score of the research group was lower than that of the control group,the difference was statistically significant (t =4.055,5.017,all P ＜ 0.05).There was no statistically significant difference in ADL index between the two groups before treatment (t =0.059,P ＞ 0.05).After treatment,the ADL index were significantly higher compared with before treatment,the differences were statistically significant (t =7.657,22.209,5.453,12.832,all P ＜ 0.05).At 7d and 14d after treatment,the ADL index score of the research group was higher than that of the control group,the difference was statistically significant (t =2.559,9.356,all P ＜ 0.05).Conclusion Ozagrel combined with edaravone is advantageous to the recovery of neural function of patients with cerebral ischemic stroke,promote the improvement of activities of adily living,with good clinical curative effect.
ABSTRACT
Objective To observe the clinical effect of sodium ozagrel combined with cinepazide treatment of cerebral arteriosclerosis , and the influence on hemorheology and blood lipid.Methods 112 cases of arteriosclerosis in patients with cerebral infarction were randomly selected from January 2015 to January 2016 in our hospital, and were randomly divided into observation group and control group ,56 cases in each group, the control group were treated with cinepazide treatment, patients in the observation group was combined with ozagrel sodium, clinical curative effect and blood rheology were compared between the two groups study, blood lipid.Results The observation group the total efficiency was significantly higher than the control group ( P<0.05 ) .After treatment, compared with before treatment, blood rheology parameters and blood lipid levels of two groups were significantly improved ( P<0.05 ) , and the patients in the observation group improved the hemorheological parameters and blood lipid level was significantly better than the control group ( P<0.05 ) .Conclusion Ozagrel sodium combined with cinepazide maleate in the treatment of cerebral arteriosclerosis process,can significantly improve the hemorheological parameters and blood lipids, and the clinical curative effect.
ABSTRACT
Objective To evaluate the effect of Qixuoxue Huoxue Tongluo decoction combined with ozagrel sodium on cerebral thrombosis and to improve cerebral ischemia-reperfusion injury. Methods 106 patients of cerebral thrombosis from April 2015 to April 2016 were divided into control group and observation group, each group of 53 patients. The patients in the control group were treated with ozagrel sodium for reperfusion. The observation group was treated with Qixiqi Huoxue Tongluo decoction and ozagrel sodium for treatment. Resulrs The levels of inflammatory factors (hs-CRP, TNF-α, etc.) in the observation group were lower than those in the observation group (P<0.05), and the two groups were compared with the observation group (P<0.05). The adverse effects of NIHSS and ADL were higher than those of the control group (P<0.05). The adverse effects of NIHSS and ADL were significantly lower than those of the control group (P<0.05) ; Conclusion Qixie Huoxue Tongluo Decoction combined with ozagrel sodium for cerebral thrombosis patients have a good therapeutic effect, for cerebral ischemia and reperfusion injury also have some improvement.
ABSTRACT
Objective To investigate the clinical effect of of rt-Pa Early Thrombolytic Therapy on the Patients with Acute Cerebral Infarction (ACI). Methods 40 patients with acute cerebral infarction were randomly divided into rt-PA group and control group, 20 cases in each group. The treatment time window was less than 3 hours. On the basis of the routine medication of cerebral infarction, rt-PA group was given rt-PA intravenous thrombolytic therapy, the control group was treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) were used to evaluate the efficacy and safety. Results The NIHSS scores of two groups after treatment were significantly improved compared with before treatment, rt-PA group improved significantly better than the control group (P<0.05); At 21 days of treatment, the excellence rate of rt-PA group was 80% and the ratio of BI≥95 was 40.00%, the excellence rate of control group was 25.0% and the ratio of BI≥95 was 20.00%, the rt-PA group was significantly higher than the control Group (P<0.01); there was no significant difference between the two groups in the mortality rate, the incidence of secondary cerebral hemorrhage and vascular restenosis in the two groups. Conclusion Within 3 hours of onset of ACI, compared with the sodium ozagrel therapy, the rt-PA intravenous thrombolytic therapy is more safe and effective in the treatment of ACI patients, and it is worthy to be widely used in clinical treatment.
ABSTRACT
Objective To evaluate the effect of Qixuoxue Huoxue Tongluo decoction combined with ozagrel sodium on cerebral thrombosis and to improve cerebral ischemia-reperfusion injury. Methods 106 patients of cerebral thrombosis from April 2015 to April 2016 were divided into control group and observation group, each group of 53 patients. The patients in the control group were treated with ozagrel sodium for reperfusion. The observation group was treated with Qixiqi Huoxue Tongluo decoction and ozagrel sodium for treatment. Resulrs The levels of inflammatory factors (hs-CRP, TNF-α, etc.) in the observation group were lower than those in the observation group (P<0.05), and the two groups were compared with the observation group (P<0.05). The adverse effects of NIHSS and ADL were higher than those of the control group (P<0.05). The adverse effects of NIHSS and ADL were significantly lower than those of the control group (P<0.05) ; Conclusion Qixie Huoxue Tongluo Decoction combined with ozagrel sodium for cerebral thrombosis patients have a good therapeutic effect, for cerebral ischemia and reperfusion injury also have some improvement.
ABSTRACT
Objective To investigate the clinical effect of of rt-Pa Early Thrombolytic Therapy on the Patients with Acute Cerebral Infarction (ACI). Methods 40 patients with acute cerebral infarction were randomly divided into rt-PA group and control group, 20 cases in each group. The treatment time window was less than 3 hours. On the basis of the routine medication of cerebral infarction, rt-PA group was given rt-PA intravenous thrombolytic therapy, the control group was treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) were used to evaluate the efficacy and safety. Results The NIHSS scores of two groups after treatment were significantly improved compared with before treatment, rt-PA group improved significantly better than the control group (P<0.05); At 21 days of treatment, the excellence rate of rt-PA group was 80% and the ratio of BI≥95 was 40.00%, the excellence rate of control group was 25.0% and the ratio of BI≥95 was 20.00%, the rt-PA group was significantly higher than the control Group (P<0.01); there was no significant difference between the two groups in the mortality rate, the incidence of secondary cerebral hemorrhage and vascular restenosis in the two groups. Conclusion Within 3 hours of onset of ACI, compared with the sodium ozagrel therapy, the rt-PA intravenous thrombolytic therapy is more safe and effective in the treatment of ACI patients, and it is worthy to be widely used in clinical treatment.
ABSTRACT
Objective To explore the clinical application effect of Shuxuening combined with ozagrel sodium in the treatment of cerebral infarction patients with psychological intervention.Methods120 patients with cerebral infarction were randomly divided into observation group and control group from January 2015 to June 2016.The control group was treated with intravenous ozagrel sodium and psychological intervention.The observation group was treated with control group based on the use of Shuxuening.ResultsThe clinical efficacy in the observation group was significantly higher than in the control group (P<0.05).The incidence of complications in the observation group was significantly lower than that in the control group (P<0.05).ConclusionThe combination of Shuxuening combined with ozagrel sodium and psychological intervention in the treatment of cerebral infarction, can effectively improve the patient's treatment efficiency, improve the physiological and psychological status of patients, and effectively reduce the treatment of patients with complications.
ABSTRACT
Objective To evaluate the clinical efficacy of urinary kallidinogenase combined with sodium ozagrel on acute cerebral infarction.Methods Totally 170 cases of acute cerebral infarction were randomly and equally divided into control group and treatment group.The control group was treated with ozagrel sodium while the treatment group was given urinary kallidinogenase combined with ozagrel sodium.The clinical efficacy, HINSS score, infarct volume, blood rheology and adverse reactions of the two groups were observed.Results There was no significant difference in such general data as gender, age, site of disease and complications between the two groups (P>0.05).The efficacy of the treatment group was significantly better than that of the control group (Z=-2.28, P=0.02).The NIHSS score before and after treatment was (23.38±3.24) vs (12.22±7.17) respectively in the control group,and (23.18±2.96) vs (9.16±6.95) in the treatment group.The effect in the treatment group was better than in the control group (t=2.83,P<0.05).The infarct volume before and after treatment was (5.99±0.60) vs (5.00±0.34)respectively in control group, and(5.99+0.62) vs (4.00±0.21)in the treatment group.The effect in the treatment group was better than in the control group (t=23.11,P<0.05).Blood rheology indexes, fibrinogen, plasma viscosity, whole blood low shear viscosity and whole blood viscosity improvement in the treatment group were better than those in the control group (t=14.67,7.35,19.70和5.33,P<0.05).The two groups were not significantly different in the incidence of adverse reactions.Conclusion Yuri Klein combined with ozagrel sodium can effectively treat acute cerebral infarction by repairing the damaged neurons and improving the prognosis of patients,without obvious adverse reactions.It is worthy of clinical promotion.
ABSTRACT
Objective To assess the efficacy and safety of urinary kallidinogenase combined with sodium ozagrel for cerebral infarction (CI), and provide references for clinical rational drug use. Methods Retrieved from Cochrane library, PubMed, CBM, FMJS, VIP, Wangfang database and CNKI ( published until January 2015), randomized controlled trails (RCT)about urinary kallidinogenase combined with sodium ozagrel for treatment of CI were included,then methodological quality were evaluated and statistical analysis of those studies were carried out by Rev Man 5.3.4 software. Results 19 RCTs were included,involving 1 747 patients. Results of Meta-analysis showed that urinary kallidinogenase combined with sodium ozagrel could significantly improve total effective rate[RR= 1.18, 95%CI(1.13, 1.23), Z= 7.97, P<0.000 01], cure rate[RR = 1.42, 95%CI(1.23, 1.64), Z= 4.86, P<0.000 1], neurological deficit scores[MD= -4.40, 95%CI(-5.36, -3.43), Z= 8.90,P<0. 000 01] and activity of daily living scores[MD = 19.14, 95%CI(17.39, 20.90), Z = 21.36, P<0.000 01]. Conclusion Urinary kallidinogenase combined with sodium ozagrel was effective in the treatment of CI, and no significant adverse reactions were observed. The combination therapy was worthy of clinical application.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of escitalopram combined with ozagrel sodium for elderly pa-tients with acute cerebral infarction complicated with anxiety and depression. METHODS:140 elderly patients with acute cerebral infarction complicating with anxiety and depression were divided into control group and observation group according to random number table method,with 70 cases in each group. Control group received routine treatment and Sodium ozagrel for injection 40-80 mg added into 0.9% Sodium chloride injection 500 ml,ivgtt,bid. Observation group was additionally given Escitalopram tablet 10 mg,qd. Both groups received treatment for 8 weeks. HAMA,HAMD,NIHSS and BI were compared between 2 groups before and after treatment,and clinical efficacy and the occurrence of ADR were observed. RESULTS:There was no statistical sig-nificance in HAMA,HAMD,NIHSS,BI before treatment and NIHSS,BI 1 week of after treatment between 2 groups(P>0.05). HAMA and HAMD of observation group 1,4,8 weeks after treatment,and NIHSS and BI of it 4,8 weeks after treatment were improved significantly;above indexes of control group were improved significantly 4,8 weeks after treatment,and the observation group was better than the control group,with statistical significance (P0.05). CONCLUSIONS:Escitalopram combined with ozagrel so-dium is significantly effective for elderly patients with acute cerebral infarction complicated with anxiety and depression,and can significantly improve anxiety,depression and neurological function with good safety.
ABSTRACT
Objective To observe the effect of kallikrein and ozagrel on hemorheology in the treatment of patients with acute cerebral infarction,provide a theoretical basis for clinical treatment.Methods 100 patients with acute cerebral infarction met the inclusion criteria were randomly divided into 50 cases of observation group and 50 cases of control group,the control group were received conventional drug therapy,the observation group were given kallikrein and ozagrel on the basis of the control group,kallikrein 0.15PNA /times,ozagrel 80mg one time,bid,14d for a course of treatment.The symptoms improvement were observed,the NIHSS score and ADL score were calculated after treatment,then the blood were extraced for detecting high shear viscosity of whole blood,red blood cell aggrega-tion index,hematocrit,fibrinogen,erythrocyte sedimentation rate,and the clinical efficacy were judged.Results The total effective rate of the observation group were 96% (48 /50),which of the control group were 66% (33 /50),the total effective of the observation group was significantly higher than the control group (χ2 =16.105,P <0.01);The high shear viscosity of whole blood,red blood cell aggregation index,hematocrit,fibrinogen,erythrocyte sedimentation rate,NHISS of the observation group and the control group after treatment were lower than before treatment (t =6.589 and 3.762,6.204 and 3.661,8.112 and 5.774,5.542 and 3.529,9.429 and 3.962,9.621 and 6.586,all P <0.05),the ADL score was significantly higher than before treatment(t =7.673 and 5.446,all P <0.05),the high shear viscosity of whole blood,red blood cell aggregation index,hematocrit,fibrinogen,erythrocyte sedimentation rate, NHISS of the observation group after treatment were lower than those of the control group (t =3.387,3.545,3.525, 3.288,3.302,4.988,all P <0.05),the ADL score was significantly higher than the control group (t =3.446,P <0.05).Conclusion The method containing kallikrein and ozagrel has exact clinical efficacy,can effectively improve blood rheology and cerebral blood perfusion ischemic area,promote neurological deficits and recover the ability of daily life,and its security is good,which is worthy of promotion.
ABSTRACT
Objective To investigate the effects of sodium ozagrel and berberine hydrochloride in the treatment of acute cerebral infarction and its effect on glucose and lipid metabolism.Methods According to the digital table,158 patients with acute cerebral infarction were randomly divided into the two groups:the control group was treated with the sodium ozagrel group and the observation group was treated combined with sodium ozagrel and berberine hydrochloride.After 2 weeks,Chinese stroke clinical neural function defect score scale and the National Institutes of Health Stroke Scale (NIHSS) was used to evaluate neurological function.The therapeutic effectiveness was assessed by ADL after treatment 1,3,6 months.The changes of glucose and lipid levels were detected by turbidimetric method.Results The total effective ratein the observation group was obviously higher than that of the control group (87.01％ vs 69.14％) (x2 =7.316,P ＜0.01).Of the above two ways of nerve function score indicateed that the observation group was significantly better than that of the control group (t =3.207,1.274,all P ＜ 0.01).ADL score of all patients was significantly better than that of before treatment with drug in the two groups after 1 month,3 months and 6 months (t =7.266 and t =8.850,t =1.429 and t =2.816,t =9.218 and t =6.739,P ＜0.01).Compared with the control group,ADL score of the observation group was significantly improved after 3 months and 6 months (t =1.163,0.932,all P ＜0.01).The significant difference was found between the control group and the observation group after 3 months and 6 months (t =7.861,5.005,all P ＞ 0.05).After the treatment,the fasting blood glucose level was reduced significantly in the observation group (t =0.859,P ＜ 0.01),total cholesteroland high-density lipoprotein,triglyceride,low density lipoprotein level were significantly decreased (t =0.257,0.114,0.378,all P ＜ 0.01),but there was no significant difference in HDL-C level (t =1.960,P ＞ 0.05).Conclusion The therapeutic effect of berberine hydrochloride combined with sodium ozagrel is better in the treatment of acute cerebral infarction,and the level of glucose and lipid metabolism was significantly decreased.
ABSTRACT
Objective To observe curative effect of sodium ozagrel combined with cobamamide and pancreatic kininogenase in patients with diabetic peripheral neuropathy (DNP). Methods Seventy-two diabetes patients with DNP in our hospital from September, 2008 to September, 2010 were randomly divided into observation group and control group. All patients were treated with cobamamide by intramuscular injection and pancreatic kininogenase taken orally. In the observation group sodium ozagrel injection were added to the treatment used in the control group. Results After one course of treatment, the total effective rate in the observation group was 91. 7% (31/36),which was better than the control group (63. 9% ,23/36) (x =7. 6, P 0. 05). After treatment, the nerve conduction velocity in the observation group significant better than those in the control group (P < 0. 05). Conclusion The treatments of sodium ozagrel combined with cobamamide and pancreatic kininogenase in diabetic peripheral neuropathy is safe and effective.
ABSTRACT
@# ObjectiveTo observe the effects and safety of combination of Ozagrel and low molecular weight heparin and rehabilitation training in the treatment of progressive cerebral infraction. Methods60 patients with progressive cerebral infraction were divided into the observation group and the control group with 30 patients in each group. 80 mg Ozagrel plus 250 ml normal saline infusion were used in the observation group, once every 12 hours, 14 days for a course of treatment, 0-4 ml low molecular weight heparin was used with subcutaneous injection every 12 hours interval time, 14 days for a course of treatment. But only Ozagrel was used in the control group. The same treatment was used in the two groups, all patients received routine rehabilitation training. Platelet and activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (Fg) were examined before and 14 days after treatment. The NIHSS score was assessed.ResultsAfter treatment, NIHSS score in both groups decreased significantly(P<0-01) while the observation group was significantly better than the control group (P<0-01). The efficiency of the observation group was 86-7%, the control group was 60-0%, the observation group was significantly higher than the control group(P<0-05). Platelet count, PT, APTT, and Fg of the two groups were in the normal range, and there was no obvious adverse reaction.ConclusionOzagrel and low molecular weight heparin and rehabilitation training is safe and effective in the treatment of progressive cerebral infraction.
ABSTRACT
Objective To investigate the clinical efficacy and safety evaluation of fibrinolytic,anticoagulant and antiplatelet drug combination treatment in patients with progressive ischemic stroke (PIS). Methods Ninety cases with PIS were randomly divided into the treatment group (47 cases) and the control group (43 cases). The patients in the control group were given combination therapy of Diemailing, Nadroparin calcium and Ozagrel,while the combination therapy of Defibrase, Diemailing, Nadroparin Calcium and Ozagrel were given in the treatment group. The plasma fibrinogen (Fib), prothrombin time (PT), part enabled prothrombin time (APTT), liver and kidney function were observed. The clinical efficacy was evaluated after 14 days treatment. Results After treatment,the total effective rate of the treatment group was 89.4% ,which was significantly higher than that of the control group (67.4%) (P ＜ 0.05). After treatment, the PT and APTT levels of the treatment group were respectively (19.76± 5.53)s and (35.43 ± 6.03)s,the control group were respectively(17.26 ± 1.49)s and (35.71±5.64) s, the PT and APTT increased significantly compared with the pre-treatment condition in both groups (P ＜ 0.05), while the difference between the two groups was not statistically significant (P ＞ 0.05). The Fib level was (1.51 ±0.42)g/L in the treatment group,and (3.10 ±0.69)g/L in the control group. In the treatment group the Fib level was significantly lower than the control group and the condition before treatment(P ＜0.05). We found no significant difference between conditions before or after the treatment in the control group (P ＞ 0.05). The incidence of adverse clinical events showed no significantly difference between the treatment group and control (P ＞0.05). Conclusions Applying of fibrinolytic, anticoagulant and antiplatelet drug combination treatment in patients with PIS has a good efficacy and safety,which is good for clinical application.
ABSTRACT
Objective To study the treatment effect of Ozagrel sodiumin on plasma levels of BNP and IL-18in patients with unstable angina pectoris. Methods 106 patients with unstable angina pectoris were treated randomly with routine therapy(n =40) and with routine therapy plus Ozagrel sodium(n = 66) for 2 weeks. Before and after 2weeks of the therapy,the changes of BNP and IL-18 were measured. Results After 2 weeks,the levels of BNP and IL-18 in routine therapy group and Ozagrel sodium treatment group were decreased than those before treatment,but after 2 weeks of the therapy,BNP and IL-18 were significantly decreased in candesartan treatment group compared with those in the control group(P ＜0. 05). Conclusion On the basic of general treatment,using the Ozagrel sodium could lower the serum levels of BNP and IL-18 in UAP,and improve stability of atherosclerosis plaque.
ABSTRACT
Objective To explore the clinical effects and safety of edaravone and ozagrel in treatment of acute ischemic stroke. Methods60 patients with a cute ischemic stroke were divided into two groups randomly,each group 30 patients.The treatment group was treated by edaravone and ozagrel,and the control group was treated by ligustrazine injection.Before and 14 days after treatment,the neurologic impairment and clinical curative effect of the two groups were evaluated respectively. ResultsThe effective rate in the treatment group was 86.6%,and that in the control group was 63.3%.The difference between the two groups was statistically significant(P＜0.05). ConclusionEdaravone and ozagrel in the treatment of acute ischemic stroke was effective and worthy of being widely used.